Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Rituxan (rituximab)
i
Other names:
IDEC 102, RG105, IDEC-C2B8, RO-452294, R 105, RG 105, IDEC-102, R105, IDEC-C2B8 anti-CD20, RO452294, RO 452294, RO 45-2294, Ro 45-2294, IDEC102, IDEC C2BB, R-105, RG-105, RO-45 2294
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(176)
News
Trials
Company:
Biogen, Roche, Zenyaku Holdings
Drug class:
CD20 inhibitor
Related drugs:
‹
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
IMM0306 (2)
IGM-2323 (2)
mosunetuzumab-axgb (2)
AR160 (2)
rituximab-arrx (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
AcellBia (rituximab biosimilar) (0)
ACTR087 (0)
ALETA-001 (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
obinutuzumab-β (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CND261 (0)
DI Leu16 IL-2 (0)
IGN002 (0)
F007 (rituximab biosimilar) (0)
GB241 (rituximab biosimilar) (0)
GSK5926371 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
AME-133v (0)
ocrelizumab (0)
XmAb13676 (0)
PRO131921 (0)
PRO-203 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
TG20 (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
IMM0306 (2)
IGM-2323 (2)
mosunetuzumab-axgb (2)
AR160 (2)
rituximab-arrx (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
AcellBia (rituximab biosimilar) (0)
ACTR087 (0)
ALETA-001 (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
obinutuzumab-β (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CND261 (0)
DI Leu16 IL-2 (0)
IGN002 (0)
(0)
GB241 (rituximab biosimilar) (0)
GSK5926371 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
AME-133v (0)
ocrelizumab (0)
XmAb13676 (0)
PRO131921 (0)
PRO-203 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
TG20 (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
›
Associations
(176)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + acalabrutinib + bendamustine
Sensitive: A1 - Approval
rituximab + acalabrutinib + bendamustine
Sensitive
:
A1
rituximab + acalabrutinib + bendamustine
Sensitive: A1 - Approval
rituximab + acalabrutinib + bendamustine
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
No biomarker
Burkitt Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + rituximab
Sensitive: A1 - Approval
venetoclax + rituximab
Sensitive
:
A1
venetoclax + rituximab
Sensitive: A1 - Approval
venetoclax + rituximab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
rituximab + polatuzumab vedotin-piiq
Sensitive: A1 - Approval
rituximab + polatuzumab vedotin-piiq
Sensitive
:
A1
rituximab + polatuzumab vedotin-piiq
Sensitive: A1 - Approval
rituximab + polatuzumab vedotin-piiq
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.